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Objective: To investigate the prognostic significance of tumor necrosis factor receptor (TNFR),-associated factor 6
(TRAF6),-and ubiquitin in gastric cancer patients.
Methods: Biopsies of the rectus abdominis muscle were obtained intra operatively from 102 gastric cancer patients
and 29 subjects undergoing surgery for benign abdominal diseases, and muscle TRAF6 and ubiquitin mRNA
expression and proteasome proteolytic activities were assessed.
Results: TRAF6 was significantly upregulated in muscle of gastric cancer compared with the control muscles. TRAF6
was upregulated in 67.65% (69/102) muscle of gastric cancer. Over expression of TRAF6 in muscles of gastric cancer
were associated with TNM stage, level of serum albumin and percent of weight loss. Ubiquitin was significantly
upregulated in muscle of gastric cancer compared with the control muscles. Ubiquitin was upregulated in 58.82%
(60/102) muscles of gastric cancer. Over expression of ubiquitin in muscles of gastric cancer were associated with
TNM (Tumor-Node-Metastasis) stage and weight loss. There was significant relation between TRAF6 and ubiquitin
expression.
Conclusions: We found a positive correlation between TRAF6 and ubiquitin expression, suggesting that TRAF6 may
up regulates ubiquitin activity in cancer cachexia. While more investigations are required to understand its
mechanisms of TRAF6 and ubiquitin in skeletal muscle. Correct the catabolic-anabolic imbalance is essential for the
effective treatment of cancer cachexia.
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Cancer cachexia is a complex metabolic condition charac-
terized by loss of skeletal muscle. Common clinical mani-
festations include muscle wasting, anemia, reduced caloric
intake, and altered immune function, which contribute to
increased disability, fatigue, diminished quality of life, and
reduced survival [1-3]. Many patients with cancer present
with weight loss at diagnosis, and much of this weight loss
can be attributed to muscle wasting. Cancer cachexia has
been viewed as an end-of-life condition in patients with
advanced or incurable malignancies that was managed pri-
marily through palliative approaches. However, cachexia
and associated skeletal muscle loss may be present early in
the progression of cancer, indicating the importance of
earlier diagnosis and treatment.* Correspondence: sunshui818@126.com; zaiyuanye@163.com
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reproduction in any medium, provided the orThe prevalence of cancer cachexia varies depending on
the type of malignancy, with the greatest frequency of
weight loss (50%–85% of patients) observed in gastrointes-
tinal, pancreatic, lung, and colorectal cancers at diagnosis
and before initiation of chemotherapy [4]. One common
mechanism associated with skeletal muscle protein
degradation in cancer cachexia is the activation of the ad-
enosine triphosphate-dependent ubiquitin-proteasome
proteolytic path way [5,6]. This system plays a major role
in muscle wasting and, more specifically, in the breakdown
of myofibrillar proteins. Certainly, the mechanisms of
muscle wasting in cancer cachexia are complex. They in-
volve multiple host and tumor factors, decreased levels of
testosterone and insulin-like growth factor-1 (IGF-1), and
decreased food intake, contributing to both antianabolic
and procatabolic processes [7,8]. The study demonstrate
that the expression level of tumor necrosis factor (α) re-
ceptor adaptor protein 6 (TRAF6), a protein involved in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Summary of characteristics of gastric cancer patients and control
Controls (n = 29) Gastric cancer (n = 102) t/χ2 P Value
Age, y 61.88 ± 6.49 62.13 ± 6.54 0.053 0.959
Sex (M:F) 21:8 72:30 0.037 0.848
Weight loss 65.50 ± 4.84 57.38 ± 6.28 2.899 0.012
BMI 24.13 ± 1.81 21.00 ± 1.31 3.96 0.001
Serum albumin, g/L 41.38 ± 6.09 33.75 ± 3.11 3.15 0.007
PNI 45.25 ± 3.62 37.18 ± 3.74 5.26 0.0001
Table 2 The expression of TRAF6 in muscle of cancer
patients
low high χ2 P Value
Percent weight loss 12.9 0.001
≥10 9 45
<10 24 24
Serum albumin,g/L 20.05 0.001
≥35 24 18
<35 9 51
TNM stage 13.33 0.001
I-II 21 18
III-IV 12 51
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is enhanced in skeletal muscle during atrophy [9,10].
Here, we analyzed the prognostic significance of tumor
necrosis factor receptor (TNFR)-associated factor 6
(TRAF6), and ubiquitin in gastric cancer patients. The
current study were to examine the expression of TRAF6
and ubiquitin in skeletal muscle specimens of patients
with gastric cancer, to explore the possible correlation
among TRAF6, ubiquitin mRNA expression and cachexia.
Methods
Patients and tissue samples
Skeletal muscle tissues were collected from one hundred
and two patients with gastric cancer (median age 61.0y,
range 42–88y; 24 male, 10 female) from the Department
of Surgery, Zhejiang Provincial People’s Hospital from
January 2008 to January 2011. Patients’ characteristics
are showed in Table 1. Diagnosis of gastric cancer was
performed by endoscopic biopsy. Twenty-nine patients
undergoing surgery for benign abdominal diseases
served as a control group, there were 12 cholelithiasis, 9
inguinal hernia, 8 hemangioma of liver. Gastric cancer
patients and controls were similar in terms of age and
sex distribution. Nevertheless, gastric cancer patients
showed a significantly lower body mass index, serum al-
bumin levels and prognostic nutritional index. Exclusion
criteria for both groups were considered: acute or
chronic renal failure, liver failure, diabetes, metabolic
acidosis, sepsis, AIDS, inflammatory bowel disease, auto-
immune disorders, chronic heart failure, and hyperthy-
roidism. The study was approved by our hospital ethics
committees. Written informed consent for the study
procedures was obtained from the patients.
Nutritional assessment
The nutritional assessment included anthropometric
[height, actual body weight, %WL, body mass index
(BMI), usual body weight], immunological (total
lymphocyte count), and biochemical (serum albumin)
indexes. Routine blood test was determined using
completely automatic blood cell count analyzer (Beck-
man-Coulter -MAXM, American). Liver function was
determined using Completely automatic biochemistry
analyzer (Beckman-Coulter SYNCHRON LX 20,American) (Table 1). The PNI(prognostic nutritional
index) was calculated as follows: PNI = 10 × serum albu-
min(g/100 ml) + 0.005 × total lymphocyte count/mm3 of
peripheral blood [11].
Muscle biopsy
A biopsy specimen was obtained from the rectus abdom-
inis muscle during the initial phase of the operation. The
anterior sheet of the rectus abdominis muscle was
opened with scissors after skin incision and dissection
through the subcutaneous fat, and a muscle biopsy speci-
men weighing about 1.0 g was obtained. The biopsy spe-
cimen was divided into two portions that were
immediately frozen in liquid nitrogen and then stored at
−80°C until analysis. No complications occurred from
the biopsy procedure.
Real-time quantitative RT-PCR
Total RNA from rectus abdominis muscle was extracted
by TRIzol reagent and cDNAs were reverse-transcribed by
Revert Aid TM reverse transcriptase. Real-time PCR was
carried out using the ABI PRISM 7700 Sequence Detec-
tion System (Applied Bio systems) at 50°C for 2 min, 95°C
for 10 min, followed by 50 cycles at 95°C for 15 s, and at
60°C for 1 min. The primers for GAPDH (224 bp) were 5'-
TGAAGGTCGGAGTCAACGG-3' (sense) and 5'- CTGG
AAGATGGTGATGGGATT-3' (antisense). The primers
for TRAF6 (134 bp) were 5'-GCCTGGGTGACAGAGTG
C-3' (sense) and 5'-AATGACTACTTATGGCTCCTTT
Figure 1 The level of TRAF6 protein in muscle of cancer patients and control.
Table 3 The expression of ubiquitin in muscle of cancer
patients
low high χ2 P Value
Percent weight loss 11.78 0.001
≥10 15 42
<10 27 18
Serum albumin,g/L 15.74 0.001
≥35 27 15
<35 15 45
TNM stage 20.52 0.001
I-II 27 12
III-IV 15 48
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5'-CCCTGGATGTGATGGTGTC-3' (sense) and 5'-CTCG
TTGTCCCTGTTGCTG-3' (antisense). The expression of
GAPDH was used to normalize that of the target genes.
Each assay was done in triplicate, the average was calcu-
late, and the expression level of TRAF6 and ubiquitin was
expressed as 2–ΔΔCt, ΔCt=Ct (Target)–Ct (GAPDH).
Immunoblotting
Cells were lysed in RIPA buffer (150 mM NaCl,
10 mM Tris, pH 7.5, 1% NP40, 1% deoxycholate, 0.1%
SDS, protease inhibitor cocktail (Roche)). Total pro-
teins were fractionated using the NuPAGE 4–12% Bis-
Tris gradient gel (Invitrogen) and transferred onto
PVDF membrane. Membranes were blocked with 5%
non-fat milk in PBS/Tween-20, and incubated with
antibodies against TRAF6 (Santa Cruz), ubiquitin
(Santa Cruz), and β-actin (Abcam).
Statistical analysis
In order to analyze the relationship among the expres-
sion of TRAF6 and ubiquitin and nutritional status of
patients (percent weight loss, serum albumin), according
to the literature [12], they were divided into two groups
(percent weight loss ≥ 10 and <10, serum albumin ≥ 35
and <35). All statistical analyses were performed using
SPSS16.0 software. Measurement data were analyzed
using the Student’s t test, while categorical data were
studied using χ2 or Fisher exact tests. Statistical signifi-
cance was set at P < 0.05.
Results
The expression of TRAF6 in muscle of control and cancer
patients
Tumor necrosis factor (α) receptor adaptor protein 6
(TRAF6), a protein involved in receptor-mediated activa-
tion of several signaling pathways, is enhanced in skel-
etal muscle during atrophy. We assessed the expression
of TRAF6 in 29 control muscles and 102 patient mus-
cles. TRAF6 was significantly upregulated in muscle of
gastric cancer compared with the control muscles
(P < 0.05). TRAF6 was upregulated in 67.65% (69/102)
muscle of gastric cancer. Overexpression of TRAF6 inmuscles of gastric cancer were associated with TNM
stage, level of serum albumin and percent of weight loss
(P > 0.05) (Table 2). We also analyze the expression of
TRAF6 in 8 muscles of control and cancer patients by
western blotting, the results show the expression of
TRAF6 in muscle of cancer patients were higher than
control (Figure 1).The expression of ubiquitin in muscle of control and
cancer patients
We assessed the expression of ubiquitin in 29 control
muscles and 102 patient muscles. Ubiquitin was signifi-
cantly upregulated in muscle of gastric cancer compared
with the control muscles (P< 0.05). Ubiquitin was upregu-
lated in 58.82% (60/102) muscles of gastric cancer. Over
expression of ubiquitin in muscles of gastric cancer were
associated with TNM stage and weight loss (P> 0.05)
(Table 3). In order to analyze the expression of ubiquitin
protein with quantitation, 8 muscle of control and cancer
patients were detectec by western blotting, the study indi-
cated the expression of ubiquitin in 5 muscle of cancer
patients were higher than control (Figure 2).Association between expression of TRAF6 and ubiquitin
Seventeen cases of gastric cancer had high expression of
both TRAF6 and ubiquitin, and eight cases of gastric
cancer had low expression of both TRAF6 and ubiquitin.
Figure 2 The level of ubiquitin protein in muscle of cancer patients and control.
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pression (χ2 =6.68; P= 0.01) (Table 4, Figure 3).
Discussion
In healthy individuals, skeletal muscle metabolism
requires a balance of anabolic and catabolic processes,
resulting in a continuous renewal of muscle proteins
without a net change in overall muscle mass. However,
in cancer cachexia and other chronic illnesses, the
muscle wasting were associated with the reduced rate of
protein synthesis, increased protein degradation, or a
combination of both contributes [13]. One common
mechanism associated with skeletal muscle protein deg-
radation in cancer cachexia is the activation of the ad-
enosine triphosphate-dependent ubiquitin-proteasome
proteolytic path way, this system plays a major role in
muscle wasting [5,6]. The study showed muscle ubiqui-
tin mRNA was hyper expressed in gastric cancer
patients compared to controls [14], the ubiquitin-
proteasome proteolytic system play important role in the
pathogenesis of muscle protein hyper catabolism in can-
cer cachexia. To investigate the role of ubiquitin expres-
sion in the skeletal muscle of gastric cancer patients. We
assessed the expression of ubiquitin in 29 control mus-
cles and 102 patient muscles. Ubiquitin was significantly
upregulated in muscle of gastric cancer compared with
the control muscles. Over expression of ubiquitin in
muscle of gastric cancer were associated with TNM
stage and weight loss.
Skeletal muscle wasting is a major reason for morbid-
ity and mortality in many chronic disease states, disuse
conditions and aging. The ubiquitin-proteasome and
autophagy-lysosomal systems are the two major proteo-
lytic pathways involved in regulation of both physio-





high low χ2 P
ubiquitin 20.05 0.001
high 51(85.0%) 9(15.0%)
low 18(42.9%) 24(57.1%)demonstrate that the expression level of tumor necrosis
factor (α) receptor adaptor protein 6 (TRAF6), a protein
involved in receptor-mediated activation of several sig-
naling pathways, is enhanced in skeletal muscle during
atrophy [9,10]. To explore the relation of TRAF6 expres-
sion in the skeletal muscle of gastric cancer patients. We
assessed the expression of TRAF6 in 29 control muscles
and 102 patient muscles. TRAF6 was significantly upre-
gulated in muscle of gastric cancer compared with the
control muscles, Overexpression of TRAF6 in muscle of
gastric cancer were associated with TNM stage, the level
of serum albumin and percent of weight loss. The study
showed overexpression of TRAF6 may play important
role in gastric cancer cachexia.
Paul’s study discover that TRAF6 possesses E3 ubiqui-
tin ligase activity causing lysine-63-linked polyubiquiti-
nation of target proteins. Muscle-wasting stimuli could
up regulate the expression of TRAF6 and auto-ubiquiti-
nation. Muscle-specific depletion of TRAF6 preserves
skeletal muscle mass in a mouse model of cancer cach-
exia or denervation. Inhibition of TRAF6 also blocks the
expression of the components of the ubiquitin-
proteasome system (UPS) and auto phagosome forma-
tion in atrophying skeletal muscle [15]. We also exam-
ined TRAF6 expression in skeletal muscle with gastricFigure 3 Association between expression of TRAF6 and
ubiquitin.
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found a positive correlation between TRAF6 and ubiqui-
tin expression, suggesting that TRAF6 may up regulates
ubiquitin activity in cancer cachexia. While more investi-
gations are required to understand its mechanisms of
TRAF6 and ubiquitin in skeletal muscle. Correct the
catabolic-anabolic imbalance is essential for the effective
treatment of cancer cachexia.
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